This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia

This study has been completed.
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: March 27, 2012
Last updated: January 19, 2017
Last verified: January 2017
This is a phase 2, open-label extension study to assess the long-term safety and efficacy of REGN727 (SAR236553) administered by subcutaneous (SC) injection in patients previously participating in the R727-CL-1003 study.

Condition Intervention Phase
Hypercholesterolemia Drug: REGN727 (SAR236553) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia

Resource links provided by NLM:

Further study details as provided by Regeneron Pharmaceuticals:

Primary Outcome Measures:
  • Incidence of AEs from baseline to end of study [ Time Frame: Baseline (Day 1) to week 218 (End of study) ]
    Incidence of AEs from baseline (Day 1) to week 218 (end of study)

Secondary Outcome Measures:
  • Percent change in LDL-C: Baseline to weeks 12, 24, 52 and 218 [ Time Frame: Baseline (Day 1) to weeks 12, 24, 52 and 218 (End of study) ]
    Percent change in calculated serum LDL-C (Low-density lipoprotein cholesterol) from baseline (average of values calculated at Screening Visit and Baseline [Day 1] visits) in the current study to weeks 12, 24, 52 and 218.

  • Changes in other lipids and other lipoproteins [ Time Frame: Baseline (Day 1) and week 218 (End of study) ]
    To evaluate the effect of REGN727 on other lipid parameters.

Enrollment: 58
Study Start Date: March 2012
Study Completion Date: December 2016
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open Label Drug: REGN727 (SAR236553)
REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Key Inclusion Criteria

  1. Prior participation in and the successful completion of the R727-CL-1003 study.
  2. Patients must be on a stable daily statin regimen for at least 3 weeks before prior to entry into the study
  3. A negative urine pregnancy at the screening/baseline visit for women of childbearing potential

Exclusion Criteria:

Key Exclusion Criteria

  1. Reported a drug-related SAE or drug-related clinical or laboratory AE in the R727-CL-1003 study that resulted in early termination or withdrawal
  2. Significant protocol deviation in R727-CL-1003, such as non-compliance by the investigator or patient
  3. LDL apheresis within 12 months before the screening/baseline visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01576484

United States, California
Mission Viejo, California, United States
Newport Beach, California, United States
Thousand Oaks, California, United States
United States, Florida
Miami, Florida, United States
Port Orange, Florida, United States
United States, Kansas
Kansas City, Kansas, United States
United States, Maine
Auburn, Maine, United States
United States, Missouri
St. Louis, Missouri, United States
United States, North Carolina
Durham, North Carolina, United States
United States, Ohio
Cincinnatti, Ohio, United States
United States, Texas
Houston, Texas, United States
Canada, Quebec
Chicoutimi, Quebec, Canada
Montreal, Quebec, Canada
Sainte-Foy, Quebec, Canada
Sponsors and Collaborators
Regeneron Pharmaceuticals
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
  More Information

Responsible Party: Regeneron Pharmaceuticals Identifier: NCT01576484     History of Changes
Other Study ID Numbers: R727-CL-1032
Study First Received: March 27, 2012
Last Updated: January 19, 2017

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on August 21, 2017